Vonoprazan Is Associated With Better Liver-Related Outcomes Compared With Proton Pump Inhibitors in Cirrhosis.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 41665246.
- Also identified by DOI 10.14309/ajg.0000000000003945.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Proton pump inhibitors (PPIs) are associated with poor outcomes in cirrhosis. Comparing impact of PPI vs potassium-channel acid blockers (PCABs) is important. Patients with cirrhosis on PCABs vs PPIs were followed for outcomes (liver-related hospitalizations/complications, mortality, and infections). Groups were compared using adjusted/unadjusted Cox-proportional hazards at 6/12 months postinitiation. Overall, 35,056 patients (31,688 PPI, 3,368 PCAB) were included. Adjusted analysis showed lower 6/12-month outcomes with vonoprazan vs PPI for mortality (adjusted hazard ratio [aHR]-0.36/0.39), infections (aHR-0.60/0.67), liver-complications (aHR-0.16/0.18), and liver-related hospitalizations (aHR-0.12/0.13), which remained largely consistent on sensitivity analyses. Patients with cirrhosis on PCABs demonstrate lower risk of poor outcomes at 6 and 12-months vs PPIs.